CN1547965A - Tea beverage and its prepn - Google Patents

Tea beverage and its prepn Download PDF

Info

Publication number
CN1547965A
CN1547965A CNA031285449A CN03128544A CN1547965A CN 1547965 A CN1547965 A CN 1547965A CN A031285449 A CNA031285449 A CN A031285449A CN 03128544 A CN03128544 A CN 03128544A CN 1547965 A CN1547965 A CN 1547965A
Authority
CN
China
Prior art keywords
tea
water
boiling
vinegar
chrysanthemum
Prior art date
Application number
CNA031285449A
Other languages
Chinese (zh)
Inventor
戴明树
Original Assignee
戴明树
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 戴明树 filed Critical 戴明树
Priority to CNA031285449A priority Critical patent/CN1547965A/en
Publication of CN1547965A publication Critical patent/CN1547965A/en

Links

Abstract

The present invention is tea beverage comprising green tea, American ginseng, longan, wolfberry fruit, orange peel, chrysanthemum, cassia seed, vinegar, water, honey, sweetener and carbonic acid gas. The preparation process includes diluting vinegar with water, adding decoction of green tea, American ginseng, longan, wolfberry fruit, orange peel, chrysanthemum and cassia seed, adding honey, sweetener and carbonic acid gas, mixing homogeneously, filtering, packing, and sterilizing. The present invention has the function of raising immunity and is delicious.

Description

一种茶饮品及其制备方法 One kind of tea drinks and preparation method

技术领域 FIELD

本发明涉及一种茶饮品及其制备方法,尤其涉及一种参茶饮品及其制备方法。 The present invention relates to a method for its preparation tea drinks, tea drinks, and particularly to a method of preparing ginseng.

背景技术 Background technique

随着广大消费者饮食结构的逐渐改变,人们突破了传统饮茶的需求,发展为饮用具有多方面保健作用的保健型茶料,开创了保健身心健康的新途径。 With the gradual change in the diet of consumers, it needs to break through the traditional tea drinking, the development of health-based material drinking tea has many health benefits, creating a new way of physical and mental health care. 但是目前市场上的茶与保健品多为共泡合饮的保健型茶料,并且保健性差,有的口味不佳,尤其是绿茶还存在肠胃不适者不宜饮用的缺点,原因是绿茶属凉性,夏季饮用,以使人感到清凉,患有胃及十二指肠溃疡者,不宜喝浓茶,由于刺激太大,易造成胃部不适。 But now tea and health care products on the market are mostly combined total of bubble tea drink health type material, and the health of the poor, and some poor taste, especially green tea, there are disadvantages upset stomach are advised not to drink, because green tea is cool summer drink, to make people feel cool, suffering from gastric and duodenal ulcers, should not drink tea, because the stimulus is too large, easily lead to stomach discomfort. 因而茶与保健品共泡合饮茶品,不能充分发挥其茶饮品的保健功能。 Thus a total of bubble tea and health care products tea products together, can not fully play its health care function tea drinks.

发明内容 SUMMARY

本发明的目的是提供一种茶饮品及其制备方法,尤其是提供一种参茶饮品及其制备方法,克服了目前茶饮品保健性差,口味不佳,肠胃不适者不宜经常饮用的缺点。 The purpose of the invention is to provide a tea beverage and its preparation method, in particular, it is to provide a method for its preparation ginseng tea drinks, tea drinks to overcome the current health of the poor, poor taste, stomach discomfort often advised not to drink shortcomings.

本发明的目的是通过以下技术方案来实现的:一种茶饮品,包括以下组分:绿茶、西洋参、桂圆肉、枸杞、橘皮、菊花、决明子、食醋、水、蜂蜜、甜味剂、碳酸气。 Object of the present invention is achieved by the following technical solutions: A tea drinks, comprising the following components: green tea, ginseng, longan, wolfberry, orange peel, chrysanthemum, cassia, vinegar, water, honey, sweeteners, carbon dioxide gas.

所述的茶饮品,优选以下重量份组分:绿茶0.8-1.2、西洋参0.01-0.03、桂圆肉0.3-0.7、枸杞0.3-0.7、橘皮0.3-0.7、菊花0.3-0.7、决明子0.3-0.7、食醋和水按(0.8-1.2)∶(4-6)比例配成100、蜂蜜适量、甜味剂适量、碳酸气适量。 The tea beverage, preferably less parts by weight of component: 0.8-1.2 green tea, ginseng 0.01-0.03, longan 0.3-0.7, 0.3-0.7 wolfberry, orange peel 0.3-0.7, 0.3-0.7 chrysanthemum, cassia 0.3 to 0.7, vinegar and water at (0.8-1.2): (4-6) 100 dubbed ratio, honey, sweetening amount, an appropriate amount of carbonic acid gas.

所述的茶饮品,最优选以下重量份组分:绿茶1、西洋参0.02、桂圆肉0.5、枸杞0.5、橘皮0.5、菊花0.5、决明子0.5、食醋和水按1∶5比例配成100、蜂蜜适量、甜味剂适量、碳酸气适量。 The tea beverage, most preferably the weight ratio of component parts: a green tea, ginseng 0.02, longan 0.5, 0.5 wolfberry, orange peel 0.5, 0.5 chrysanthemum, cassia 0.5, vinegar and water at a ratio of 1:5 dubbed 100, honey, sweetening amount, an appropriate amount of carbonic acid gas.

所述茶饮品的制备方法,包括以下步骤:取绿茶加水煎煮一次,加入西洋参、桂圆肉、枸杞、橘皮、菊花、决明子再煎煮三次,煎煮液过滤;将食醋用水按比例稀释后,加入上述过滤液,再加入蜂蜜、甜味剂和碳酸气,混匀,过滤,罐装,灭菌,即得。 The preparation of tea drinks, comprising the steps of: boiling water to take a green tea, ginseng added, longan, wolfberry, orange peel, chrysanthemum, cassia and then three times with boiling, the decoction was filtered; the vinegar diluted with water in proportion after adding the above solution was filtered, then add honey, and carbonic acid gas sweetening, mixing, filtering, canned, sterilized, i.e., too.

所述第一次煎煮绿茶与水比例可为1∶5,所述后三次煎煮加入组分与水比例可为1∶3。 The first green tea with boiling water ratio may 1:5, after the addition of the three components with boiling water ratio may 1:3.

所述灭菌可为100℃蒸气灭菌或紫外灭菌。 The sterilization may be 100 ℃ steam sterilization or UV sterilization.

所述煎煮可为先温火煮沸后,再猛火煎煮15-30分钟,最好煎煮20分钟。 The boiling temperature may be a fire-before-boil, boiling again raging 15-30 minutes, preferably boiling for 20 minutes.

所述食醋可以为低度食醋,所述水最好为纯净水。 The vinegar vinegar may be low, the water is preferably purified water.

本发明中所提供的参茶饮品,其中各组份具有优良的保健性能,且各组份之间具有良好的协调作用。 The present invention is provided in the ginseng tea beverage, wherein the components having an excellent health properties, and have good coordination action between the components. 西洋参分为补养药,具有抗衰者、抗疲劳、开心益智等保健作用;枸杞为养阴药,能滋养肝肾;橘皮为理气药,能温胃健脾,理气化痰;菊花为解表药物,散热解表,清肝明目,并有解毒作用,治头痛,眩晕,目赤,心胸烦热,疗疮、肿毒;决明子为清热药,能清肝、益肾,明目。 American ginseng into tonics, those having anti, anti-fatigue, and other health effects fun puzzle; wolfberry Yangyin medicine to nourish the liver and kidney; orange peel is qi drug, can warm the stomach and spleen, qi and phlegm; chrysanthemum relieving drugs, relieving the heat, Liver eyesight and detoxification, headache, dizziness, red eyes, mind vexed hot, sore, swollen poison; Cassia is antipyretic, to Liver, kidney, eyesight .

茶与枸杞子合饮。 Wolfberry fruit drink tea together. 不但对肝肾阴虚所致的头晕目眩、视力减退、腰膝酸软、遗精等久服甚为有效,而且对高血脂、高血压、动脉硬化、糖尿病等也有一定辅助疗效。 Not only for liver and kidney caused by dizziness, vision loss, weak waist, nocturnal emission and other Jiufu very effective, but also for high cholesterol, hypertension, atherosclerosis, diabetes also have some secondary effects.

茶与西洋参片合饮。 American ginseng tea and piece together drink. 利用西洋参补阴虚功能和味甘辛凉的性质,调整茶味制成西洋参茶,具有良好的益肺养胃、滋阴津、清虚火、去低热的功效。 The use of American ginseng supplement and functional deficiency Xinliang sweet nature, made of ginseng tea flavor adjustment, with good Yifei Yang Wei, Jin Yin, Qing Xu fire, to the effect of low heat.

茶与橘皮共饮。 Sip tea and orange peel. 可宽中理气、去热解痰、抗菌清炎。 It may be wide in the gas, to the pyrolysis sputum, antibacterial cleaning inflammation. 咳嗽多痰者饮之有益。 Cough who drink useful.

食醋,味酸,性温,无毒,理诸药,消肿痛。 Vinegar, Pickle, warm, non-toxic, treatment of various drugs, swelling and pain.

本发明具有以下优点:1、对肠胃不适者可以适量长期饮用;2、由于本参茶饮品中所加入的组分,能显著提高人体抗能,增加人体对病病的抵抗力,提高机体免疫功能。 The present invention has the following advantages: 1. The amount of the long-term gastrointestinal discomfort can drink; 2, since the present ginseng tea drinks added component, can significantly improve the anti-body can increase the body's resistance to disease disease, improved immune Features.

3、本发明组分为天然植物药,无毒副作用。 3, natural herbal component of the present invention, no toxic side effect.

4、加入辅料矫味剂,使本品口感好。 4, flavoring materials added to make the product taste good.

本发明毒性安全性评价:一、第一阶段试验对本发明进行了小鼠口服急性毒性(LD50)的测定。 Safety evaluation of the present invention Toxicity: a first phase of the present invention has an oral acute toxicity in mice (LD50) was determined.

1、动物 昆明远交系小鼠(雌雄各半)40只,体重180-220g,由安徽肿瘤研究所实验动物中心提供。 1, outbred Animals Kunming mice (male and female) 40, weighing 180-220 g, provided by Experimental Animal Center Anhui Cancer Institute. 动物实验室为恒温24±1℃,相对湿度为50-70%,人工照明(时相:12小时明,12小时暗),分缸饲养,每缸5只,喂以普通小鼠块料,自由饮水。 Animal laboratory temperature 24 ± 1 ℃, relative humidity 50-70%, artificial lighting (phase: 12 hours light, 12 hours dark), keeping sub-cylinder, 5 per cylinder, fed with normal mice blocks, free access to water.

2、实验方法样品为本发明浓缩液,每ml相当于19ml本发明原药,以下同。 2, the sample test method of the present invention, the concentrate, 19ml per ml equivalent to the original drug of the present invention, hereinafter the same.

小鼠按霍恩氏法随机分配,设四个组,每组10只,雌雄各半,各组剂量分别为10580mg/kg,5010mg/kg,2140mg/kg,1000mg/kg。 Mice were randomly assigned Horn 'method, a set of four groups of 10 each, male and female, each dose group were 10580mg / kg, 5010mg / kg, 2140mg / kg, 1000mg / kg. 服用前断食14小时,饮水不限。 Fasted 14 hours before administration, water is not limited. 按剂量一次灌胃给服,每10克体重灌胃0.3ml,给服后2小时喂食,观察14天。 Orally dosed once for serving, per 10 grams of body weight orally 0.3ml, serving for 2 hours after feeding, observed for 14 days. 每天观察记录动物中毒的表现和死亡情况。 Observe and record the performance of animal poisoning deaths every day. 死亡动物进行尸检,每7天称重一次。 Dead animals were necropsied, weighed every 7 days.

小鼠按霍恩氏法随机分配,设四个组,每组10只,雌雄各半,各组剂量分别为22000mg/kg,10580mg/kg,5010mg/kg,2140mg/kg,给服方法同上。 Mice were randomly assigned by Horn 'method, provided four groups of 10 each, male and female, each dose group were 22000mg / kg, 10580mg / kg, 5010mg / kg, 2140mg / kg, to service as above.

3、计算方法用简化机率单位通式计算下列参数,动物半数致死剂量(LD50)。 3, the following parameters calculation method, a simplified animal probit formula LD50 (LD50).

4、实验结果本发明对小鼠口服LD50>10580mg/kg,属实际无毒物质,雌雄小鼠的LD50无明显差别(表1)。 4, the experimental results of the present invention is oral LD50 in mice> 10580mg / kg, actually no poisonous substances, LD50 male and female mice no significant difference (Table 1).

表1 本发明对小鼠急性毒性(LD50)测定结果剂量 动物数(只) 死亡数(只)(mg/kg) 雄 雌 雄 雌1000 5 5 0 02140 5 5 0 05010 5 5 0 010580 5 5 0 0本发明对小鼠急性毒性(LD50)测定结果剂量 动物数(只) 死亡数(只)(mg/kg) 雄 雌 雄 雌2140 5 5 0 05010 5 5 0 010580 5 5 0 022000 5 5 0 05、判定:可以进行第二阶段试验二、第二阶段试验鉴于本品大鼠经口LD50>10580mg/kg,第二阶段中的蓄积毒性实验从略,按规定做如下三项致突变试验。 Results Number of doses (only) deaths (only) (mg / kg) Animals in Table 1 of the present invention was measured in mice Acute toxicity (LD50) female and male female and male 1000 5,500,214,055,005,010,550. 5. 5 0 0 010 580 results number of doses (only) deaths (only) (mg / kg) male and female male and female 214,055,005,010,550 010 580 55002200055005 animals of the invention determination of the acute toxicity in mice (LD50), determined : phase II trial can be two, in view of a phase II trial of this product in rats orally LD50> 10580mg / kg, the second stage is omitted cumulative toxicity test, do the following three predetermined mutagenicity test.

(一)Ames试验1、试验方法:按国内规定的统一方法试验。 (A) Ames Test 1, Test method: according to the provisions of the domestic unified approach to testing. 样品测试前经处理。 Sample test treated.

2、菌种:新近由美国加利福尼亚大学Ames实验室引进的鼠伤寒沙门氏菌菌株,TA98、TA100、TA97、TA102四株,经五项特性鉴定,表明酶活性良好。 2, strain: newly introduced by the United States Ames Laboratory, University of California, strains of Salmonella typhimurium, TA98, TA100, TA97, TA102 four by five characterization, show good activity.

3、S-9肝微粒酶,由本室新近制备,经用已知致突变物鉴定,表明酶活性良好。 3, S-9 liver microsomal enzymes, recently prepared by the chamber, identified by the use of known mutagens, show good activity.

4、剂量与对照:按上述条件与方法,同时做了下述不同剂量试验,各种重复三次。 4, with the control dose: methods and conditions described above, while doing the following different doses of the test, the various repeated three times. 采用标准平皿掺入法,每一平皿加受试物0.1ml。 Using the standard plate incorporation assay, each test plate was added 0.1ml.

①本发明1mg/皿②本发明2.5mg/皿③本发明5mg/皿④本发明10mg/皿阴性对照:不加S-9活化系统丝裂霉素0.5μg/10μl,阳性对照:加S-9活化系统叠氮化钠5μg/10μl。 ① 1mg / dish of the present invention, the present invention ② 2.5mg / dish of the present invention ③ 5mg / dish of the present invention ④ 10mg / dish Negative control: without S-9 activation system mitomycin 0.5μg / 10μl, Positive control: add S- 9 activation system sodium azide 5μg / 10μl.

5、计算培养基上长出的回变菌落结果见表2表2 本发明Ames试验结果样品名称和剂量 每平板回变菌落数(μg/m) TA96 TA100 TA97 TA102-S9 +S9 -S9 +S9 -S9 +S9 -S9 +S9自发回变 27 36 14 165 126 108 216 222本发明 25 32 137 158 120 115 196 2121000本发明 28 33 140 158 126 113 190 2082140本发明 27 30 148 157 122 121 188 2085010本发明 23 34 140 163 115 114 201 20410580阴性对照 26 38 147 148 116 113 201 206阳性对照 >2000 >2000 >2000 >2000 >2000 >2000 >2000 >2000 5, calculated on the grown medium revertant colonies The results in Table 2 Ames test results of the samples in Table name and dose of the present invention the number of revertant per plate (μg / m) colonies TA96 TA100 TA97 TA102-S9 + S9 -S9 + S9 -S9 + S9 -S9 + S9 spontaneous revertant 28331402730148 1,571,221,211,882,085,010 1,581,261,131,902,082,140 the present invention 273,614,165,126,108 216 222 2,532,137,158,120,115,196 2,121,000 iNVENTION invention 2,334,140,163,115,114,201 20.41058 million negative control 2,638,147,148,116,113,201 206 positive control> 2000> 2000> 2000> 2000> 2000> 2000> 2000> 2000

试验结果可见,各试验浓度下,各皿回变菌菌落数均末超过自发回变数的2倍,而各阳性对照组显示了强烈诱变作用。 Test results can be seen, the concentration of each test, each dish revertant colonies in the number of bacteria exceeding that of spontaneous late variables twice, and each positive control group showed a strong mutagenic effects.

根据Ames试验结果判断标准,认为本次测试每皿10580ug/皿的剂量下,未显示致突然变阳性作用。 The results of Ames test criteria that this test at a dose per dish 10580ug / dish, not shown actuator suddenly positive effect.

结论:本次测试的本发明未呈致突变阳性作用。 Conclusion: The present invention was not tested positive for mutagenic effect.

(二)小鼠骨髓嗜多染红细胞微核试验1、方法(1)样品:同上(2)动物由安徽省肿瘤研究所提供的昆明种健康小鼠,雌雄共50只,体重240-260克;共分成五组,每组10只,雌雄各半。 (Ii) mouse bone marrow micronucleus test 1, Method (1) Sample: supra (2) provided by the Institute of Animal Tumor Anhui healthy Kunming mice were 50 male and female, weighing 240-260 g ; were divided into five groups of 10 each, male and female.

(3)剂量分组及方法:I组阴性对照组(蒸馏水),V组阳性对照组(环磷酰胺50mg/kg),其它实验组分别为II组1300mg/kg,III组2610mg/kg,IV组5010mg/kg本样品,按0.1ml/10g容量灌胃,采用两次给服法,服两次间隔时间为24小时,末次给服6小时后,小鼠颈椎脱白处死,取出两侧股骨,用小牛血清冲洗骨髓腔内容物,经离心、涂片、固定、染色、每只鼠镜检计数1000个嗜多染红细胞中出现微核的细胞畸变率并以千分率表示。 (3) Dose and grouping methods: I negative control group (distilled water), V positive control group (cyclophosphamide 50mg / kg), the other groups were Group II 1300mg / kg, III group 2610mg / kg, IV group 5010mg / kg of this sample according to 0.1ml / 10g orally capacity, to the use of two regimens, taken twice the interval time of 24 hours after the last administration for 6 hours, the cervical off white mice were sacrificed and the femur on both sides, flushing the marrow cavity contents with calf serum, centrifuged, smears, fixed, stained, viable count of cells per mouse micronucleus aberration occurs 1000 polychromatic erythrocytes and expressed in parts per thousand.

2结果小鼠骨髓细胞微核的试验:结果见表3,由表3可见,给与小鼠1300、2610、5010mg/kg体重本发明,雄性小鼠骨髓嗜多染红细胞微核率分别为1.2‰,1.4‰‰,1.6‰;雌性小鼠微核率分别为1.2‰、1.4‰。 Mouse 2 Test Results Bone Marrow Cells: The results in Table 3, seen from Table 3, the mice administered 1300,2610,5010mg / kg body weight of the present invention, the male mouse bone marrow cell micronucleus rate of 1.2 were ‰, 1.4 ‰‰, 1.6 ‰; micronucleus rate female mice were 1.2 ‰, 1.4 ‰. 1.4‰与阴性对照组(蒸馏水)微核率,雄性小鼠为1.0%,雌性小鼠为1.0%,经统计学处理P>0.05,无显著性差异,阳性对照组(环磷酰胺)微核率雄性小鼠为18.8%,雌性小鼠为25.2%,经统计学处理比较,P<0.05,有显著性差异。 1.4 ‰ with the negative control group (distilled water) micronucleus rate, 1.0% male mice, female mice was 1.0%, the statistical P> 0.05, no significant difference, positive control group (cyclophosphamide) micronuclei 18.8% of male mice, female mice was 25.2% compared statistically, P <0.05, significant difference. 试验结果表明,本发明对小鼠骨髓嗜多染红细胞微核试验,未发现有明显的致突变作用。 The results show that the present invention is of mouse bone marrow polychromatic erythrocyte micronucleus test, it showed no significant mutagenic effect.

表3 本发明小鼠骨髓嗜多染红细胞微核检测剂量 动物数(只) 观察嗜多染红细胞数 雄 性 雌 性mg/kg 雄 雌 (个/组) 含微核细 微核率 含微核细 微核率雄 雌 胞数 (‰) 胞数 (‰)0 5 5 5000 5000 5 1.0 5 1.01300 5 5 5000 5000 6 1.2 6 1.22610 5 5 5000 5000 7 1.4 7 1.45010 5 5 5000 5000 8 1.6 7 1.4环磷酰胺 5 5 5000 5000 108 21.6 13.3 26.6结论:可以认为本发明对小鼠骨髓细胞微核出现率无影响。 Table 3 mice invention PCE Micronucleus detecting the number of doses used in animal cells (only) the number of polychromatic erythrocytes were observed in male female mg / kg female and male (/ group) micronucleated nuclei of fine fine nucleation rate micronucleated the number of male and female cells (‰) number (‰) cell 055500050005 1.0 5 1.01300 55500050006 1.2 6 1.22610 55500050007 1.4 7 1.45010 55500050008 cyclophosphamide 55 1.6 7 1.4 21.6 13.3 26.6 50005000108 conclusion: that the present invention can have no effect on micronucleus rate of mouse bone marrow cells.

(三)小鼠睾丸染色体畸变分析1、方法:(1)样品:同前(2)动物为安徽省肿瘤研究所提供的昆明种小鼠,雄性25只,体重320-350克。 (C) a mouse testis chromosome aberration analysis process: (1) Sample: with the former (2) for the Cancer Institute Animal Kunming mice provided Anhui, 25 male, weighing 320-350 g.

(3)剂量分组及方法按体重随机区组分成5组,I组为阴性对照组(蒸馏水),II组1300mg/kg,III组2610mg/kg,IV组5010mg/kg本发明,V组为阳性对照组(环磷酰胺50mg/kg)。 (3) dose packets and the method is divided into weight-randomized group 5 group, I group as negative control (distilled water), II group 1300mg / kg, III group 2610mg / kg, IV group 5010mg / kg of the present invention, V groups of positive control group (cyclophosphamide 50mg / kg). 小鼠按0.2mL/10g体重灌胃,每日一次,连续5天,观察计数第一次分裂中期细胞100个,记录统计畸变细胞数,计算畸变率。 Mice were 0.2mL / 10g body weight orally once a day for 5 days, the first count was observed metaphase cells 100, records the number of atypical cells, calculated distortion.

表4 小鼠睾丸染色体畸变分析试验结果剂量 动物数 分析细胞 单 价 体 断 片mg/kg (只) 数(个) 常染色体 畸变率 性染色体 畸变率 数量 畸变率% % %I0 5 500 6 1.2 14 2.8 0 0II1300 5 500 7 1.4 16 3.2 1 0.2III2610 5 500 7 1.4 18 3.6 1 0.2IV5000 5 500 8 1.6 16 3.2 1 0.2V环磷酰胺 5 500 34 6.8 76 15.2 36 7.2*50*P<0.01从表中可见阳性对照组与阴性对照组及各试验组相比均有非常显著性差异(P<0.01),阴性对照组及本发明各组的畸变率均在正常值范围内。 Table 4 mouse testis chromosome aberration assay results analyzed for cell number of animals dose univalent fragments mg / kg (only) (unit) autosomal chromosome aberrations whims distortion aberration Number%%% I0 5 500 6 1.2 14 2.8 0 0II1300 5 500 7 1.4 16 3.2 1 0.2III2610 5 500 7 1.4 18 3.6 1 0.2IV5000 5 500 8 1.6 16 3.2 1 0.2V cyclophosphamide 5 500 34 6.8 76 15.2 36 7.2 * 50 * P <0.01 As seen from table positive control group and negative control group and all test groups were compared to the very significant difference (P <0.01), the distortion rate of the negative control group and groups of the present invention is within the normal range.

结论:本发明在小鼠睾丸染色体畸变分析试验中未显示对生殖细胞的危害作用。 Conclusion: The present invention in mouse testis chromosome aberration assay test harmful effects of germ cells is not shown.

三、对本品安全性毒理学评价第一、二阶段试验综合结论1、本发明样品的小鼠,小鼠经口LD50>100g/kg,属实际无毒物质。 Third, the product toxicological evaluation of a first, a second stage test integrated conclusion, mice, mice of the present invention is orally sample LD50> 100g / kg, actually no poisonous substances.

2、本发明样品的Ames实验、小鼠骨髓嗜多染红细胞微核试验,小鼠睾丸染色体畸变分析试验三项致突变试验,均为阴性,与对照蒸馏水一样,表明样品无致突变性。 2, Ames test samples of the present invention, the mouse bone marrow micronucleus test of mouse testis chromosome aberration analysis of three tests for mutagenicity tests were negative, and distilled water as the control, the sample showed no mutagenicity.

综合以上各点,认为本发明没有毒副作用。 For all these reasons, that there was no toxic side effects of the invention.

具体实施方式 Detailed ways

实施例1称取以下组份,重量(千克):绿茶1、西洋参0.015、桂圆肉0.5、枸杞0.5、橘皮0.5、菊花0.5、决明子0.5、食醋和水按1∶5配成100、蜂蜜0.1,甜味剂0.1,碳酸气0.005。 Example 1 The following components were weighed, weight (kg): 1 green tea, ginseng 0.015, longan 0.5, 0.5 wolfberry, orange peel 0.5, 0.5 chrysanthemum, cassia 0.5, vinegar and water at 100 1:5 dubbed, honey 0.1, 0.1 sweeteners, carbonated 0.005.

制备方法:取绿茶加水煎煮,先温火煮沸,再猛火煎煮20分钟;加入西洋参、桂圆肉、枸杞、橘皮、菊花、决明子再煎煮三次,煎法同前;煎煮液过滤;将食醋用水按比例稀释配成100千克后,加入上述过滤液,再加入蜂蜜、甜味剂和碳酸气,混匀,过滤,得过滤液,罐装100℃蒸气灭菌,即得。 Preparation Methods: green tea boiling water, the first warm fire to boil, then raging boiling for 20 min; added ginseng, longan, wolfberry, orange peel, chrysanthemum, cassia and then three times with boiling, frying method supra; decoction was filtered; after dilution of vinegar with water dubbed by 100 kg, was added to the filtrate, then adding honey, and carbonic acid gas sweetening, mixing, filtration, and the filtrate too, canned 100 ℃ steam sterilization, ie.

实施例2称取以下组份,重量单位为千克:绿茶0.8、西洋参0.02、桂圆肉0.3、枸杞0.3、橘皮0.3、菊花0.3、决明子0.3、食醋和水按0.8∶5配成100、蜂蜜0.05,甜味剂0.05,碳酸气0.002。 Example 2 weighed the following components, by weight in kg: 0.8 Green tea, ginseng 0.02, longan 0.3, 0.3 wolfberry, orange peel 0.3, 0.3 chrysanthemum, cassia 0.3, vinegar and water at 100 0.8:5 dubbed, honey 0.05, 0.05 sweeteners, carbonated 0.002.

制备方法:同实施例1,不同在于猛火煎煮时间为15分钟。 Preparation: same as in Example 1, except that the raging boiling time of 15 minutes.

实施例3称取以下组份,重量单位为千克:绿茶1.2、西洋参0.01、桂圆肉0.7、枸杞0.7、橘皮0.7、菊花0.7、决明子1.2、食醋和水按0.8∶6配成100、蜂蜜0.5,甜味剂0.5,碳酸气0.006。 Example 3 said embodiment takes the following components, by weight in kg: 1.2 Green tea, ginseng 0.01, longan 0.7, 0.7 wolfberry, orange peel 0.7, 0.7 chrysanthemum, cassia 1.2, vinegar and water at 100 0.8:6 dubbed, honey 0.5, 0.5 sweeteners, carbonated 0.006.

制备方法:同实施例1,不同在于煎煮时间为30分钟。 Preparation: same as in Example 1, except that the boiling time is 30 minutes.

Claims (8)

1.一种茶饮品,包括以下组分:绿茶、西洋参、桂圆肉、枸杞、橘皮、菊花、决明子、食醋、水、蜂蜜、甜味剂、碳酸气。 A tea beverage comprising the following ingredients: green tea, ginseng, longan, wolfberry, orange peel, chrysanthemum, cassia, vinegar, water, honey, sweeteners, carbon dioxide gas.
2.根据权利要求1所述的茶饮品,包括以下重量份组分:绿茶0.8-1.2、西洋参0.01-0.03、桂圆肉0.3-0.7、枸杞0.3-0.7、橘皮0.3-0.7、菊花0.3-0.7、决明子0.3-0.7、食醋和水按(0.8-1.2)∶(4-6)比例配成100、蜂蜜适量、甜味剂适量、碳酸气适量。 The tea drinks according to claim 1, comprising by weight parts of the following components: 0.8-1.2 green tea, ginseng 0.01-0.03, 0.3-0.7 longan, wolfberry 0.3-0.7, 0.3-0.7 orange peel, chrysanthemum 0.3-0.7 , Cassia 0.3-0.7, vinegar and water at (0.8-1.2): (4-6) 100 dubbed ratio, honey, sweetening amount, an appropriate amount of carbonic acid gas.
3.根据权利要求1所述的茶饮品,包括以下重量份组分:绿茶1、西洋参0.02、桂圆肉0.5、枸杞0.5、橘皮0.5、菊花0.5、决明子0.5、食醋和水按1∶5比例配成100、蜂蜜适量、甜味剂适量、碳酸气适量。 Tea drinks according to claim 1, comprising by weight parts of the following components: a green tea, ginseng 0.02, longan 0.5, 0.5 wolfberry, orange peel 0.5, 0.5 chrysanthemum, cassia 0.5, vinegar and water at 1:5 100 dubbed ratio, honey, sweetening amount, an appropriate amount of carbonic acid gas.
4.权利要求1-3之一所述茶饮品的制备方法,包括以下步骤:取绿茶加水煎煮一次,加入西洋参、桂圆肉、枸杞、橘皮、菊花、决明子再煎煮三次,煎煮液过滤;将食醋用水按比例稀释后,加入上述过滤液,再加入蜂蜜、甜味剂和碳酸气,混匀,过滤,罐装,灭菌,即得。 Tea decoction take a boiling water was added ginseng, longan, wolfberry, orange peel, chrysanthemum, cassia then boiling for three times: The method of preparing the tea drinks one of claim 1-3, comprising the steps of filtration; vinegar diluted with water after scale, was added to the filtrate, then adding honey, and carbonic acid gas sweetening, mixing, filtering, canned, sterilized, i.e., too.
5.根据权利要求4所述的茶饮品的制备方法,所述第一次煎煮绿茶与水比例为1∶5,所述后三次煎煮加入组分与水比例为1∶3。 The method of preparing tea beverage according to claim 4, said first boiling water with green tea 1:5 ratio, after the addition of the three components with boiling water ratio 1:3.
6.根据权利要求4所述的茶饮品的制备方法,所述灭菌为100℃蒸气灭菌或紫外灭菌。 The method of preparing tea beverage according to claim 4, the sterilization is a steam sterilization 100 ℃ or ultraviolet sterilization.
7.根据权利要求1所述的茶饮品的制备方法,所述煎煮为先温火煮沸后,再猛火煎煮15-30分钟。 The preparation of tea drinks according to claim 1, after the first boiling temperature fire to boil, boiling for 15-30 minutes and then raging.
8.根据权利要求1所述的茶饮品的制备方法,所述猛火煎煮为20分钟。 8. A method for preparing tea drinks according to claim 1, the raging boiling 20 minutes.
CNA031285449A 2003-05-08 2003-05-08 Tea beverage and its prepn CN1547965A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNA031285449A CN1547965A (en) 2003-05-08 2003-05-08 Tea beverage and its prepn

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CNA031285449A CN1547965A (en) 2003-05-08 2003-05-08 Tea beverage and its prepn

Publications (1)

Publication Number Publication Date
CN1547965A true CN1547965A (en) 2004-11-24

Family

ID=34322174

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA031285449A CN1547965A (en) 2003-05-08 2003-05-08 Tea beverage and its prepn

Country Status (1)

Country Link
CN (1) CN1547965A (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1921929A4 (en) * 2005-08-12 2009-08-05 Multi Formulations Ltd Supplemental dietary composition including caffeine, taurine and ginseng
CN100525636C (en) 2005-02-01 2009-08-12 王玺成 Tea beverage of longan and chrysanthemum
CN100579378C (en) 2007-08-07 2010-01-13 山西大学 Tartary buckwheat vinegar tea beverage and its production process
CN101095551B (en) 2007-07-19 2010-12-01 钟旭 Method for preparing health-care carbonic acid beverage
CN101653184B (en) 2009-08-25 2012-02-22 广州市凯虹香精香料有限公司 An acid pneumatic herbal tea
CN102885149A (en) * 2012-10-30 2013-01-23 陈志冲 Health-care milk tea and preparation method thereof
CN103518878A (en) * 2013-09-26 2014-01-22 朱奕 Honey vinegar beverage with function of lubricating intestines and invigorating stomach and preparation method thereof
CN104171156A (en) * 2014-08-25 2014-12-03 黄家亨 Rice vinegar tea beverage capable of clearing away heat and toxic materials and preparation method thereof
CN104522804A (en) * 2014-12-22 2015-04-22 广西南宁桂知科技有限公司 Chrysanthemum tea vinegar beverage and preparation method thereof
CN105707595A (en) * 2016-02-02 2016-06-29 田家丰 Beverage capable of preventing and treating computer xeroma and preparation method of beverage
CN105876558A (en) * 2016-06-25 2016-08-24 张阳康 Healthcare beverage and production process thereof

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN100525636C (en) 2005-02-01 2009-08-12 王玺成 Tea beverage of longan and chrysanthemum
EP1921929A4 (en) * 2005-08-12 2009-08-05 Multi Formulations Ltd Supplemental dietary composition including caffeine, taurine and ginseng
CN101095551B (en) 2007-07-19 2010-12-01 钟旭 Method for preparing health-care carbonic acid beverage
CN100579378C (en) 2007-08-07 2010-01-13 山西大学 Tartary buckwheat vinegar tea beverage and its production process
CN101653184B (en) 2009-08-25 2012-02-22 广州市凯虹香精香料有限公司 An acid pneumatic herbal tea
CN102885149A (en) * 2012-10-30 2013-01-23 陈志冲 Health-care milk tea and preparation method thereof
CN103518878A (en) * 2013-09-26 2014-01-22 朱奕 Honey vinegar beverage with function of lubricating intestines and invigorating stomach and preparation method thereof
CN104171156A (en) * 2014-08-25 2014-12-03 黄家亨 Rice vinegar tea beverage capable of clearing away heat and toxic materials and preparation method thereof
CN104522804A (en) * 2014-12-22 2015-04-22 广西南宁桂知科技有限公司 Chrysanthemum tea vinegar beverage and preparation method thereof
CN105707595A (en) * 2016-02-02 2016-06-29 田家丰 Beverage capable of preventing and treating computer xeroma and preparation method of beverage
CN105876558A (en) * 2016-06-25 2016-08-24 张阳康 Healthcare beverage and production process thereof

Similar Documents

Publication Publication Date Title
CN100551250C (en) Health-care tea
CN101336704A (en) Processing method of Chinese herbal medicine health tea
CN102283300B (en) Bitter buckwheat herbal tea and preparation method thereof
CN103283890A (en) Health-care dark tea
CN101084774A (en) Method for preparing sugar-free natural health beverage
CN102578671B (en) Alcoholism-relieving liver-protecting botanical nutritional beverage and making method thereof
CN1265715C (en) Bitter gourd cold tea and its production method
CN101066412A (en) Brain nourishing and eyesight improving tea
CN102342352A (en) Health-preserving flower and fruit tea and preparation method thereof
CN103719423A (en) Lucid ganoderma tea and preparation method thereof
CN102293303B (en) Fire-clearing health-care tea
CN1480055A (en) Nuntritioin enhanced health tea for computer users and preparation method
CN1389130A (en) Mutritious herb tea and its making process
CN102293430B (en) Beverage with functions of antioxidation and immunity enhancing, and preparation method thereof
CN100493385C (en) Health care beverage of sugar cane juice
CN1332983A (en) Lotus type health care beverage
CN102389010B (en) Fagopyrum tataricum tea and preparation method thereof
CN1078118A (en) Emblic leafflower fruit series beverage and preserved fruit
CN101007065A (en) Cool tea buccal tablets and its preparation method
CN101653179B (en) Health protection tea
CN101653181A (en) Health protection tea and process thereof
CN1572155A (en) Aloe tea and manufacturing method thereof
CN1824058B (en) Medicine and food dual purpose Chinese medicinal product for preventing and treating nightblindness and its manufacturing method
CN103070265A (en) Substitution tea and preparation method
CN101919982A (en) Medicinal combination for relieving alcoholism and protecting liver and functional chewing gum prepared therefrom

Legal Events

Date Code Title Description
C06 Publication
C02 Deemed withdrawal of patent application after publication (patent law 2001)